arrow
H

Henk-Jan Guchelaar

leiden university medical center
H指数:79
被引数:2.6万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

A Precise Activity System for Pharmacogenetics Based on Estimation of CYP2D6 A llelic Percentage Activity from the International CEPAM Database

基于国际CEPAM数据库估算<i>CYP2D6</i>A等位基因活性百分比的精确药效遗传学活性系统

2026-11-110
PRE
DPYD c.85 T > C, DPYD c.496 A>G, and DPYD c.2194 G>A and severe toxicity to fluoropyrimidines in PREPARE and Alpe-DPD trials. An original study and meta-analysis

<em>DPYD</em> c.85 T &gt; C、<em>DPYD</em> c.496 A&gt;G和<em>DPYD</em> c.2194 G&gt;A与氟嘧啶类药物的严重毒性:一项原始研究和荟萃分析

2026-09-110
OAAI
Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between TPMT/NUDT15 and thiopurines

荷兰药物基因组学工作组(DPWG)关于TPMT/NUDT15与硫嘌呤类药物基因-药物相互作用的指南

2025-11-290
PRE
Integration of germline pharmacogenomic burden to predict fluoropyrimidine-related toxicity – A secondary analysis of the PREPARE trial

整合生殖系药代基因组负担以预测氟嘧啶相关毒性的研究——PREPARE试验的二次分析

2025-09-250
PRE
Real world effectiveness of durvalumab in stage III unresectable non-small cell lung cancer: what is the role of PD-L1 expression?

III期不可切除非小细胞肺癌 durvalumab 的真实世界有效性:PD-L1 表达的作用是什么?

2025-07-170
OAAI
Pharmacogenetic Implementation Studies—Lessons Learned From the PREPARE Study

药物基因组学实施研究——来自PREPARE研究的经验教训

2025-06-240
OAAI
Dose-individualisation of fluoropyrimidines in DPYD wild-type patients: Final results from the Alpe2U study

氟嘧啶类药物的剂量个体化在DPYD野生型患者中的研究:Alpe2U研究的最终结果

2024-09-011
PRE